Blood markers could spot sepsis risk early

NCT ID NCT02545478

Recruiting now Knowledge-focused Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at whether early signs of inflammation in the blood can help identify which patients with infections are at risk for serious complications like sepsis. Researchers will follow 4,200 adults with confirmed or suspected infections, as well as healthy controls, to see how well these biomarkers predict death or organ failure within 28 days. The goal is to improve early detection and treatment of severe infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better tools for early detection of severe infections, helping doctors intervene sooner and potentially reduce deaths from sepsis.
What could go wrong: This is an observational study, not a treatment trial. It may not directly improve patient outcomes, and the biomarkers might not be accurate enough for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease infectious disease with sepsis Inflammation inflammatory disease Pathologic Processes Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFECTION INFLAMMATION SEPSIS

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.